ANI Pharmaceuticals Targets Acute Gout With Cortrophin Push
ANI Pharmaceuticals ANIP is leaning harder into its Rare Disease franchise as growth increasingly concentrates around Purified Cortrophin Gel. The next step is a sharper commercial push into acute gouty arthritis flares, which management is treating as a meaningful new demand pocket. At the same time, the company is working to restore momentum in its ...












